Clinical study to investigate the effects of olmesartan and azelnidipine in patients with hypertesnion and arteriosclerosis obliterans
Not Applicable
- Conditions
- Patients with essential hypertension and arteriosclerosis obliterans(ASO)
- Registration Number
- JPRN-C000000236
- Lead Sponsor
- Cardiovascular Hospital of Central Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1) Fontane classification III or IV 2) Immediate requirement for surgical operation 3) Myocardial infarction, unstable angina pectoris, stroke or transient ischemic atttack within 6 months before giving informed consent 4) Deep-vein thrombosis within 3 months before giving informed consent 5) Malignancy that requires treatment 6) Liver dysfunction (AST and ALT>100IU/L) 7) Renal dysfunction (creatinine>3.0mg/dL)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy Changes from baseline in blood pressure (Casual blood pressure and ABPM) Changes from baseline in intima media thickness in femoral arteries and carotid arteries Safety Adverse event and laboratory tests
- Secondary Outcome Measures
Name Time Method